×
About 758 results

ALLMedicine™ Gamma-glutamyltransferase Center

Research & Reviews  276 results

The Prognostic Value of the Albumin to Gamma-Glutamyltransferase Ratio in Patients with...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626189
Disease Markers; Liu W, Zhang F et. al.

Nov 30th, 2021 - Albumin to gamma-glutamyltransferase ratio (AGR) is a newly developed biomarker for the prediction of patients' prognosis in solid tumors. The purpose of the study was to establish a novel AGR-based nomogram to predict tumor prognosis in patients ...

Factors associated with liver cancer prognosis after hepatectomy: A retrospective cohor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542119
Medicine Yuan Y, Yang F et. al.

Oct 23rd, 2021 - This article was to investigate risk factors influencing liver cancer prognosis after hepatectomy.Patients undergoing hepatectomy after being diagnosed with liver cancer in Zhongshan Hospital Affiliated to Xiamen University were collected in the r...

Leaf paste of Telfairia occidentalis favourably modulates deleterious effects associate...
https://doi.org/10.1515/jcim-2021-0151
Journal of Complementary & Integrative Medicine; Owumi SE, Olugbami JO et. al.

Oct 22nd, 2021 - Diethylnitrosamine (DEN) is found in workplaces, processed meats, tobacco smoke, whiskey, etc. It is capable of forming DNA-adducts. Fluted pumpkin (Telfairia occidentalis [To]) is a medicinal plant, and its herbal preparations have been employed ...

Anthropometric Measurements and Correlations to Glucometabolic and Cardiovascular Risk ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310453
Journal of Obesity; Aldenbäck E, Johansson HE

Jul 31st, 2021 - Abdominal obesity is associated with hypertension, increased fasting glucose, HbA1c, and cholesterol. Body mass index (BMI) is frequently used to measure and define obesity and as inclusion criteria for bariatric surgery. Sagittal abdominal diamet...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  4 results

Combination Antiretroviral Therapy (cART) for PBC
https://clinicaltrials.gov/ct2/show/NCT03954327

May 19th, 2021 - Primary endpoint: Greater than 10% difference in mean percentage of alkaline phosphatase (ALP) reduction in cART vs. placebo at 6 and 12 months. Secondary endpoints: Serum biochemistries bilirubin, aspartate aminotransferase (AST), alanine aminotr...

Glutathione-rich Foods for Type 2 Diabetes
https://clinicaltrials.gov/ct2/show/NCT04386187

Nov 12th, 2020 - This research study is a randomized, controlled trial that will evaluate whether diet and nutrition education on, and short-term partial feeding of, specific plant foods high in the antioxidant glutathione will impact total glutathione status, gam...

Pirfenidone and Advanced Liver Fibrosis.
https://clinicaltrials.gov/ct2/show/NCT04099407

Sep 23rd, 2019 - The study will be conducted in compliance with International Standard good clinical practices (GCPs) and the Declaration of Helsinki. The protocol was approved by local Institutional Review Board and registered in clinical trials.gov. Clinical and...

Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort."
https://clinicaltrials.gov/ct2/show/NCT02196064

Aug 5th, 2015 - This is a retrospective analysis of the prospective multicenter, observational "HEPAVIR HEPATIC SAFETY Cohort" (NCT01908660), in which the hepatic safety of the three-drug combination TDF/FTC/RPV will be assessed. A total of 176 patients will be i...

see more →

News  22 results

FDA Approves Adjuvant Nivolumab for High-Risk Urothelial Carcinoma
https://www.onclive.com/view/fda-approves-adjuvant-nivolumab-for-high-risk-urothelial-carcinoma

Aug 23rd, 2021 - The FDA has approved nivolumab (Opdivo) for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection, irrespective of prior neoadjuvant chemotherapy, nodal involvement or PD...

Camidanlumab Tesirine Under Investigation in Relapsed/Refractory Hodgkin Lymphoma
https://www.onclive.com/view/camidanlumab-tesirine-under-investigation-in-relapsed-refractory-hodgkin-lymphoma

Mar 16th, 2021 - The safety and efficacy of the antibody-drug conjugate (ADC) camidanlumab tesirine (ADCT-301) is under investigation in patients with relapsed/refractory Hodgkin lymphoma as part of a phase 2 clinical trial (NCT04052997), which recently completed ...

PD-1 Inhibitor Spartalizumab Plus Dabrafenib/Trametinib Active in BRAF+ Melanoma
https://www.onclive.com/view/pd1-inhibitor-spartalizumab-plus-dabrafenibtrametinib-active-in-braf-melanoma

Dec 5th, 2020 - Georgina V. Long, BSc, PhD, MBBS The triplet of the PD-1 inhibitor spartalizumab, dabrafenib (Tafinlar), and trametinib (Mekinist) led to a complete response (CR) in more than 40% of patients with previously untreated advanced BRAF V600—mutant me...

Triplet Therapy With Novel PD-1 Inhibitor Holds Promise in Melanoma
https://www.onclive.com/view/triplet-therapy-with-novel-pd1-inhibitor-holds-promise-in-melanoma

Dec 5th, 2020 - The addition of a novel PD-1 inhibitor to a combination of BRAF inhibitor dabrafenib (Tafinlar) and MEK inhibitor trametinib (Mekinist) is being tested to determine whether the triplet is safe and effective for patients with metastatic or unresect...

Triplet Therapy May Be on the Horizon for BRAF-Mutant Melanoma
https://www.onclive.com/view/triplet-therapy-may-be-on-the-horizon-for-brafmutant-melanoma

Dec 5th, 2020 - Antoni Ribas, MD, PhD The past decade of drug discovery has brought a dramatic expansion in the number of new therapies to treat patients with advanced or metastatic melanoma in 2 modalities: checkpoint blockade immunotherapies and molecularly ta...

see more →